Pediatric PK/PD Phase I Trial of Pexidartinib in Relapsed and Refractory Leukemias and Solid Tumors Including Neurofibromatosis Type I-Related Plexiform Neurofibromas.

MLA

Boal, Lauren H., et al. “Pediatric PK/PD Phase I Trial of Pexidartinib in Relapsed and Refractory Leukemias and Solid Tumors Including Neurofibromatosis Type I-Related Plexiform Neurofibromas.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 26, no. 23, Dec. 2020, pp. 6112–21. EBSCOhost, https://doi.org/10.1158/1078-0432.CCR-20-1696.

APA

Boal, L. H., Glod, J., Spencer, M., Kasai, M., Derdak, J., Dombi, E., Ahlman, M., Beury, D. W., Merchant, M. S., Persenaire, C., Liewehr, D. J., Steinberg, S. M., Widemann, B. C., & Kaplan, R. N. (2020). Pediatric PK/PD Phase I Trial of Pexidartinib in Relapsed and Refractory Leukemias and Solid Tumors Including Neurofibromatosis Type I-Related Plexiform Neurofibromas. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 26(23), 6112–6121. https://doi.org/10.1158/1078-0432.CCR-20-1696

Chicago

Boal, Lauren H, John Glod, Melissa Spencer, Miki Kasai, Joanne Derdak, Eva Dombi, Mark Ahlman, et al. 2020. “Pediatric PK/PD Phase I Trial of Pexidartinib in Relapsed and Refractory Leukemias and Solid Tumors Including Neurofibromatosis Type I-Related Plexiform Neurofibromas.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 26 (23): 6112–21. doi:10.1158/1078-0432.CCR-20-1696.